KROS (Keros Therapeutics) EBIT per Share: $-3.73 (TTM As of Mar. 2026)

What is Keros Therapeutics EBIT per Share?

Keros Therapeutics KROS +3.54% 30 EBIT per Share is $-3.73 as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,178 Biotechnology companies, Keros Therapeutics ranks worse than 84889.56% on this metric.

Keros Therapeutics's EBIT per Share for the three months ended in Mar. 2026 was $-1.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.73.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Keros Therapeutics's EBIT per Share or its related term are showing as below:

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Keros Therapeutics was -25.90% per year. The lowest was -153.10% per year. And the median was -65.15% per year.

KROS's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 15.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Keros Therapeutics's EBIT for the three months ended in Mar. 2026 was $-25.88 Mil.

Keros Therapeutics (NAS:KROS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Keros Therapeutics EBIT per Share Related Terms

Keros Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics EBIT per Share Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT per Share

Get a 7-Day Free Trial

-2.43

-4.15

-5.20

-5.60

1.79

Keros Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT per Share	Get a 7-Day Free Trial															3.71	-0.98	-0.38	-1.05	-1.32

30GF Score

Keros Therapeutics Inc KROS

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Keros Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Keros Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

	EBIT per Share		(A: Dec. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	67.569	/	37.859
=	1.78

Keros Therapeutics's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

	EBIT per Share		(Q: Mar. 2026 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.877	/	19.630
=	-1.32

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.73

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of $-3.73 mean?

Keros Therapeutics (KROS) has a EBIT per Share of $-3.73 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #999999 out of 1178 companies in the Biotechnology industry.

Is Keros Therapeutics' EBIT per Share too high?

Keros Therapeutics' current EBIT per Share is $-3.73. Based on the distribution chart, Keros Therapeutics ranks #999999 out of 1178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Keros Therapeutics' EBIT per Share compare to CDXS and CAMP?

According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #999999 out of 1178 companies for EBIT per Share. This places Keros Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Biotechnology company?

The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current EBIT per Share is $-3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Keros Therapeutics stock overvalued right now?

Keros Therapeutics (KROS) has a current EBIT per Share of $-3.73. The current EBIT per Share is $-3.73. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current EBIT per Share is $-3.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CDXS CAMP VYGR QTTB RNA TNXP ALEC CNTN IMUX WHWK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

30GF Score

Get the complete analysis for KROS

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.26

Price

View KROS Analysis

See EBIT per Share data for all stocks →